Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606111 | 1.00 | FFAR4 (0.48) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL30940604 | 0.91 | USP2 (0.58) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL5808428 | 0.91 | USP2 (0.58) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL30940599 | 0.91 | USP2 (0.58) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL3909824 | 0.91 | USP2 (0.42) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL15365231 | 0.90 | USP2 (0.56) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL10616236 | 0.84 | USP2 (0.55) | FFAR4FFAR1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL13655125 | 0.83 | — | — | |
| SCHEMBL327431 | 0.83 | FFAR1 (0.62) | FFAR4FFAR1NFKB1GPR84 | |
| SCHEMBL30787358 | 0.83 | FFAR1 (0.62) | FFAR4FFAR1NFKB1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528959-A | Preparation method of 1-decyne-5-alcohol and derivative thereof | 上海凌凯科技股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20250197338-A1 | SYNTHESES OF COMPOUNDS USEFUL FOR PRODUCING TREPROSTINIL | UNITED THERAPEUTICS CORPORATION (US) | 2025-06-19 | — | — | US | disclosed |
| CN-119528959-A | Preparation method of 1-decyne-5-alcohol and derivative thereof | 上海凌凯科技股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119528959-A | Preparation method of 1-decyne-5-alcohol and derivative thereof | 上海凌凯科技股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20070004942-A1 | Method of preparation of an alkyne with an optically active hydroxyl group in the beta or gamma position of a triple bond and intermediates obtained | SHASUN PHARMA SOLUTIONS LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197338-A1 | SYNTHESES OF COMPOUNDS USEFUL FOR PRODUCING TREPROSTINIL | PTGIS, PTGES, PTGIR | FFAR4 3453/4885FFAR1 3051/4885USP2 3859/4885 |
| US-20070004942-A1 | Method of preparation of an alkyne with an optically active hydroxyl group in the beta or gamma position of a triple bond and intermediates obtained | LBR, ICOSLG, IGLV6-57 | FFAR4 2740/4885FFAR1 2934/4885USP2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.